ABSTRACT Introduction Major Depressive Disorder (MDD) is a chronic, relapsing, and
remitting disorder affecting over 250 million persons each year worldwide. More than 50% of …

Introduction Current treatment of major depressive disorder (MDD) warrants critical
reexamination. Initial treatment response rates are modest and drop dramatically after 3 …

Background: In patients who are not responding to antidepressant pharmacotherapy,
information regarding the future probability of response with the same treatment is scarce …

Antidepressant–placebo response-differences (RDs) in controlled trials have been
declining, potentially confounding comparisons among older and newer drugs. For clinically …

Objective: In clinical practice, acute antidepressant treatment is often applied for several
months until remission is achieved. However, data on treatment outcomes beyond 8 weeks …

Background The efficacy, limitations, and methods of studying antidepressant treatment
continued beyond initial weeks of acute major depression remain incompletely resolved …

Introduction Many antidepressants are indicated for the treatment of major depression. Two
network meta-analyses have provided the most comprehensive assessments to date …

Objective Model-based meta-analysis was used to describe the time-course and dose-effect
relationships of antidepressants and also simultaneously investigate the impact of various …

OBJECTIVE: The primary objective of this article is to review the literature regarding the
speed of response to antidepressant drugs and potential strategies to accelerate the …

Background: Major depressive disorder (MDD) is a highly burdensome health condition, for
which there are numerous accepted pharmacological and psychological interventions …